These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Lanthanum carbonate--a first line phosphate binder? de Freitas D; Donne RL; Hutchison AJ Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822 [TBL] [Abstract][Full Text] [Related]
7. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Sprague SM Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307 [TBL] [Abstract][Full Text] [Related]
8. Lanthanum carbonate: a postmarketing observational study of efficacy and safety. Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T; J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966 [TBL] [Abstract][Full Text] [Related]
9. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Wilson R; Zhang P; Smyth M; Pratt R Curr Med Res Opin; 2009 Dec; 25(12):3021-8. PubMed ID: 19845495 [TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients. Almirall J; Betancourt L; Esteve V; Valenzuela MP; López T; Ruiz A; Martínez-Ocaña JC; Calvet X Int Urol Nephrol; 2012 Feb; 44(1):231-6. PubMed ID: 21069570 [TBL] [Abstract][Full Text] [Related]
11. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits. Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039 [TBL] [Abstract][Full Text] [Related]
12. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Mehrotra R; Martin KJ; Fishbane S; Sprague SM; Zeig S; Anger M; Clin J Am Soc Nephrol; 2008 Sep; 3(5):1437-45. PubMed ID: 18579668 [TBL] [Abstract][Full Text] [Related]
13. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies. Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194 [TBL] [Abstract][Full Text] [Related]
14. Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules. Mukai I; Yoshizawa T; Kumagai J; Takahashi N; Tsuchiya S Ther Apher Dial; 2014 Jun; 18 Suppl 1():28-33. PubMed ID: 24953764 [TBL] [Abstract][Full Text] [Related]
15. Lanthanum carbonate: safety data after 10 years. Hutchison AJ; Wilson RJ; Garafola S; Copley JB Nephrology (Carlton); 2016 Dec; 21(12):987-994. PubMed ID: 27479781 [TBL] [Abstract][Full Text] [Related]
16. [Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate]. Tatsuta K; Shigematsu T Clin Calcium; 2009 Feb; 19(2):219-23. PubMed ID: 19182362 [TBL] [Abstract][Full Text] [Related]
17. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Hutchison AJ; Laville M; Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536 [TBL] [Abstract][Full Text] [Related]
18. REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain. Torregrosa JV; González-Parra E; González MT; Cannata-Andía J Nefrologia; 2014 May; 34(3):360-8. PubMed ID: 24849057 [TBL] [Abstract][Full Text] [Related]
19. [Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control]. Arenas MD; Malek T; Álvarez-Ude F; Gil MT; Moledous A; Reig-Ferrer A Nefrologia; 2010; 30(5):522-30. PubMed ID: 20613851 [TBL] [Abstract][Full Text] [Related]